Literature DB >> 16328593

Antibody-based targeted therapy for gastric cancer.

Florian Lordick, Christian Peschel, Jörg Rüdiger Siewert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16328593     DOI： 10.1007/s10120-005-0345-4

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  16 in total

1.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Authors:  Manish A Shah; David Ilson; David P Kelsen
Journal:  J Clin Oncol       Date:  2005-03-28       Impact factor: 44.544

2.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors:  M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

Review 3.  Chemotherapy for advanced gastric cancer.

Authors:  A D Wagner; W Grothe; S Behl; G Kleber; A Grothey; J Haerting; W E Fleig
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 4.  Bevacizumab--current status and future directions.

Authors:  Rachel Midgley; David Kerr
Journal:  Ann Oncol       Date:  2005-06-06       Impact factor: 32.976

5.  Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.

Authors:  Takuo Takehana; Kazuyoshi Kunitomo; Koji Kono; Fumiaki Kitahara; Hidehiko Iizuka; Yoshiro Matsumoto; Masayuki A Fujino; Akishi Ooi
Journal:  Int J Cancer       Date:  2002-04-20       Impact factor: 7.396

Review 6.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Authors:  José Baselga; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

7.  Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system.

Authors:  Armando Gamboa-Dominguez; Claudia Dominguez-Fonseca; Leticia Quintanilla-Martinez; Edgardo Reyes-Gutierrez; Dan Green; Arturo Angeles-Angeles; Raymonde Busch; Christine Hermannstädter; Jörg Nährig; Karl-Friedrich Becker; Ingrid Becker; Heinz Höfler; Falko Fend; Birgit Luber
Journal:  Mod Pathol       Date:  2004-05       Impact factor: 7.842

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Expression of epidermal growth factor receptor in gastric carcinomas.

Authors:  Takuo Takehana; Kazuyoshi Kunitomo; Shioto Suzuki; Koji Kono; Hideki Fujii; Yoshiro Matsumoto; Akishi Ooi
Journal:  Clin Gastroenterol Hepatol       Date:  2003-11       Impact factor: 11.382

10.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.

Authors:  K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; M Sowa
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860
View more
  3 in total

1.  [Response prediction--early response evaluation. Consequences for surgical oncology].

Authors:  J R Siewert; F Lordick
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 2.  Trastuzumab: in HER2-positive metastatic gastric cancer.

Authors:  Jamie D Croxtall; Kate McKeage
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

3.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  Gini F Fleming; Michael W Sill; Kathleen M Darcy; D Scott McMeekin; J Tate Thigpen; Lisa M Adler; Jonathan S Berek; Julia A Chapman; Paul A DiSilvestro; Ira R Horowitz; James V Fiorica
Journal:  Gynecol Oncol       Date:  2009-10-18       Impact factor: 5.482
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.